OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 03, 2017 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will report its first quarter 2017 financial results and provide a clinical update on May 9, 2017. In conjunction with this announcement, Ocera will host a conference call and live audio webcast on May 9, 2017 at 4:30 p.m. Eastern Time to both review the financial results and provide an update on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a debilitating liver disorder and significant burden on the healthcare system.
The audio webcast can be accessed under “Presentations & Events” in the Investor Relations section of the Company’s website at www.ocerainc.com.
Domestic investors wishing to participate in the call should dial (844) 419-1758 and international investors should dial (209) 905-5955. The conference ID is 17133971. Investors can also access the call at http://edge.media-server.com/m/p/mkgis75d.
Replays of the call will be available on the Company’s website through June 9, 2017. Domestic investors can access the replay by dialing (844) 419-1758 and international investors can access the replay by dialing (209) 905-5955. The conference ID to access the reply is 17133971.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please visit www.ocerainc.com.
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
